abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 02월 26일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제115회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Purine scaffold Hsp90 inhibitors as mitochondria targeting anticancer and theranostics agents

등록일
2015년 2월 12일 14시 01분 18초
접수번호
0880
발표코드
KCS2.O-7 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 10시 : 45분
발표형식
구두발표
발표분야
Oral Presentation for Young International Chemists
저자 및
공동저자
PAINADATHTHOMASAJESH, 유자형1,*
울산과학기술대학교(UNIST) 자연과학부/화학과, Korea
1울산과학기술대학교(UNIST) 자연과학부 화학과, Korea
Mitochondria, the powerhouse of cell are a potential target in cancer treatment. Heat shock proteins (Hsp) and their paralogs have major role in coordinating the various functions including cell proliferation, metabolism and even apoptosis. The mitochondrial pool of Hsp90 and its mitochondrial paralog, TRAP1, suppresses cell death and reprograms energy metabolism in cancer cells; therefore, Hsp90 and TRAP1 have been suggested as target proteins for anticancer drug development. On the other hand, theranostics refers to an appealing new approach to drug development wherein therapeutic modalities are combined with those associated with diagnostic imaging. The field has emerged as an interdisciplinary research area involving chemistry, material science, biology, and medicine that combine diagnostics and therapeutics, enabling early detection, targeted drug delivery and release, and monitoring of therapeutic response with the aid of imaging modalities in a single procedure. In this context, purine-scaffold Hsp90 inhibitor series has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer. In this work we describe the design and synthesis of a few purine based molecules for mitochondrial TRAP1 targeting and theranostics application.

상단으로